Literature DB >> 11598028

Effect of attenuated Salmonella enterica serovar Typhimurium expressing a Streptococcus mutans antigen on secondary responses to the cloned protein.

C Jespersgaard1, P Zhang, G Hajishengallis, M W Russell, S M Michalek.   

Abstract

Attenuated Salmonella enterica serovar Typhimurium has been used for targeted delivery of recombinant antigens to gut- and nose-associated lymphoid tissues. Contradictory reports have described the effect of preexisting immunity to the antigen delivery vehicle. We decided to examine this discrepancy by studying the effect of immunizing mice by the intranasal (i.n.) route with Salmonella expressing an insoluble protein and to study the ability to augment recall responses by boosting with either Salmonella-expressed protein or purified soluble protein alone. The glucan-binding domain (GLU) of the enzyme glucosyltransferase (GTF), which is an important virulence factor of Streptococcus mutans, was recombinantly expressed in the insoluble phase in S. enterica serovar Typhimurium, and the immunogenicity of this construct was studied in mice. We examined the induction of primary immune responses by insoluble GLU polypeptide delivered in Salmonella at week 1 (groups 1 and 2) and recall responses after a week 15 boost with either Salmonella expressing GLU (group 1) or purified GLU polypeptide (groups 2 and 3). Group 4 served as the control and received phosphate-buffered saline alone by the i.n. route. Significant anti-GLU serum immunoglobulin G (IgG) levels were seen in groups 1, 2, and 3 at week 18 (P < 0.001), i.e., 3 weeks after the booster immunization. Mice in group 2, who received Salmonella followed by GLU, had the highest GLU-specific IgG levels among all groups. The serum IgG levels persisted in all responding groups for at least 7 weeks after the boost (week 22). The IgG2a/IgG1 subclass ratio of serum anti-GLU antibodies in group 1 significantly increased after the boost. These results support the induction of a type 1-like immune response to GLU after primary and booster immunizations with Salmonella expressing GLU. On the other hand, group 2 mice, which received Salmonella expressing GLU as the primary dose and soluble protein as the booster dose, exhibited a shift from a type 1-like to a more type 2-like immune response to GLU following the boost. These results indicate that S. enterica serovar Typhimurium is an excellent delivery vehicle for the insoluble and recombinantly expressed GLU of GTF and that this construct was especially effective in priming the host for a secondary response to soluble GLU polypeptide.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598028      PMCID: PMC100033          DOI: 10.1128/IAI.69.11.6604-6611.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Sequence analysis of the gtfB gene from Streptococcus mutans.

Authors:  T Shiroza; S Ueda; H K Kuramitsu
Journal:  J Bacteriol       Date:  1987-09       Impact factor: 3.490

2.  Correlates of protection induced by live Aro- Salmonella typhimurium vaccines in the murine typhoid model.

Authors:  J A Harrison; B Villarreal-Ramos; P Mastroeni; R Demarco de Hormaeche; C E Hormaeche
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

3.  Isolation of a glucan-binding domain of glucosyltransferase (1,6-alpha-glucan synthase) from Streptococcus sobrinus.

Authors:  G Mooser; C Wong
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

Review 4.  Role of Streptococcus mutans in human dental decay.

Authors:  W J Loesche
Journal:  Microbiol Rev       Date:  1986-12

5.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Authors:  D Nardelli-Haefliger; R B Roden; J Benyacoub; R Sahli; J P Kraehenbuhl; J T Schiller; P Lachat; A Potts; P De Grandi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Induction of protective immunity against Streptococcus mutans colonization after mucosal immunization with attenuated Salmonella enterica serovar typhimurium expressing an S. mutans adhesin under the control of in vivo-inducible nirB promoter.

Authors:  Y Huang; G Hajishengallis; S M Michalek
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

7.  Expression and immunogenicity of an Echinococcus granulosus fatty acid-binding protein in live attenuated Salmonella vaccine strains.

Authors:  J A Chabalgoity; J A Harrison; A Esteves; R Demarco de Hormaeche; R Ehrlich; C M Khan; C E Hormaeche
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

8.  The immune response to a B-cell epitope delivered by Salmonella is enhanced by prior immunological experience.

Authors:  B L Whittle; N K Verma
Journal:  Vaccine       Date:  1997-11       Impact factor: 3.641

9.  A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes.

Authors:  S Tabor; C C Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

10.  Functional and immunogenic characterization of two cloned regions of Streptococcus mutans glucosyltransferase I.

Authors:  C Jespersgaard; G Hajishengallis; T E Greenway; D J Smith; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

View more
  8 in total

1.  Enhanced immunogenicity of a genetic chimeric protein consisting of two virulence antigens of Streptococcus mutans and protection against infection.

Authors:  Ping Zhang; Christina Jespersgaard; Leticia Lamberty-Mallory; Jannet Katz; Yan Huang; George Hajishengallis; Suzanne M Michalek
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.

Authors:  Heinz Arnold; Dirk Bumann; Melanie Felies; Britta Gewecke; Meike Sörensen; J Engelbert Gessner; Joachim Freihorst; Bernd Ulrich von Specht; Ulrich Baumann
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

3.  Oral immunization with attenuated Salmonella enterica serovar Typhimurium encoding Cryptosporidium parvum Cp23 and Cp40 antigens induces a specific immune response in mice.

Authors:  Alvaro J Benitez; Nina McNair; Jan R Mead
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

4.  PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.

Authors:  Wei Xin; Yuhua Li; Hua Mo; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2009-08-17       Impact factor: 3.441

5.  Role of B7 costimulatory molecules in immune responses and T-helper cell differentiation in response to recombinant HagB from Porphyromonas gingivalis.

Authors:  Ping Zhang; Michael Martin; Qiu-Bo Yang; Suzanne M Michalek; Jannet Katz
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

6.  Influence of promoter, gene copy number, and preexisting immunity on humoral and cellular responses to a vectored antigen delivered by a Salmonella enterica vaccine.

Authors:  Manvendra Saxena; Peter J Coloe; Peter M Smooker
Journal:  Clin Vaccine Immunol       Date:  2008-11-12

Review 7.  Pre-existing immunity against vaccine vectors--friend or foe?

Authors:  Manvendra Saxena; Thi Thu Hao Van; Fiona J Baird; Peter J Coloe; Peter M Smooker
Journal:  Microbiology       Date:  2012-11-22       Impact factor: 2.777

8.  Recombinant Salmonella Bacteria Vectoring HIV/AIDS Vaccines.

Authors:  Nyasha Chin'ombe; Vurayai Ruhanya
Journal:  Open Virol J       Date:  2013-12-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.